Novel Remyelination AssayOligodendrocytes wrap around glass micropillars, allowing high-throughput assays of potential remyelination agents.
Axon Transport Deficits
Myelin and Axons Don’t Form a Uniform Union
Innate Differences in Demyelination
Welcome to the Multiple Sclerosis Discovery Forum
A conference in Cambridge, Massachusetts, outlined progress and challenges in turning computational modeling into actionable knowledge in MS and other brain disorders
A variant of a gene called SLC9A9 appears significantly more often in people with MS who fail to respond to interferon β therapy
About 20% of patients do not meet the diagnostic criteria of clinically isolated syndrome (CIS) based on radiological and clinical evidence. Patients who do not fit the CIS diagnostic criteria may yet have oligoclonal bands distinct to CSF, increased IgG synthesis rate and IgG index and must be treated as if they carried a diagnosis of CIS.
An animal model that presents an alternative to EAE suggested a role for sodium channel blockers in neuroprotection. This led directly to a successful human trial of phenytoin, which was presented at last week’s AAN meeting.
We surveyed our readers, and you gave us a few surprises
Every Friday, MSDF editors use a curated PubMed search to link to every newly published MS-related paper. Here’s how we do it.
Tools that will help investigators conceive and perform experimental work:
The Data Visualization section presents MS-related data in new ways, making it easy for viewers to discover unexpected relationships
Our latest data visualization presents a set of word clouds that allow you see the most common terms used in scientific studies describing multiple sclerosis clinical trials.
- Drug-Development Pipeline consolidates key information about compounds under investigation for therapeutic use
We've recently added 13 new trials, updated information on 28 trials, and added 74 other pieces of information. The drugs with important additions and changes are alemtuzumab, BAF312, BIIB033, daclizumab, dalfampridine, dimethyl fumarate, fingolimod, glatiramer acetate, interferon β-1a, interferon β-1b, laquinimod, mitoxantrone, naltrexone, natalizumab, phenytoin, rituximab, RPC1063, and teriflunomide.
- Tissue Repositories lists features of the world's tissue repositories and brain banks, including rules of engagement and contact information
- MSGene provides a comprehensive, unbiased and regularly updated collection of genetic association studies performed on multiple sclerosis phenotypes
- Clinical Trials lists sources of information about MS clinical trials
Meetings and Events catalogs future and past meetings of interest to the MS-research community
- Funding Opportunities provides information about where to obtain grants
- Jobs offers descriptions of available positions
Member Directory displays profiles of MS-research community members
Bulletin Board allows MSDF members to post notices
Useful Links lists helpful resources elsewhere on the web
Amyloid has potent anti-inflammatory abilities which may explain what it is trying to do in Alzhe
Most Popular Content
- Talking to Reporters: 13 Tips for Researchers
- MS Patient, Ph.D.: Lightning (and the Ice Bucket Challenge) Doesn’t Strike Twice
- Phase 1 Results Reported for Anti-LINGO-1 Remyelination Agent
- Remyelination: Are Exosomes Containing microRNA the Answer?
- MS Research Roundup: August 29, 2014
- “Long Life” Protein Klotho Powers Remyelination in Mice
- More Than Meets the Eye
- The Paradox of Daclizumab
- MS Research Roundup: April 8, 2014
- MS Patient, Ph.D.: PPMS: A New Hope?
- What’s the Role of Myelin Oligodendrocyte Glycoprotein in NMO?
- Portable Neuromodulation Device May Improve Walking in MS Patients
- Rare Family Cluster of MS Reveals New Clues
- Innate Differences in Demyelination
- MS Research Roundup: September 29, 2014
- “No great discovery was ever made without a bold guess,” Sir Isaac Newton
- Is Cognitive MS a Distinct Entity?
- MS Research Roundup: August 21, 2014
- International Progressive MS Alliance Announces New Research Grants
- Phase 2 Trial Suggests RPC1063 Is as Effective as—and Safer Than—Fingolimod
- MS Research Roundup: October 3, 2014
- MS Research Roundup: October 28, 2014
- Some Astrocytes Appear to Promote Progressive MS
- MS Family Planning 101: Should DMTs Be Discontinued Before and During Pregnancy?
- Precision medicine in chronic disease management: The MS BioScreen.
- RRMS and CIS—Baseline Characteristics
- 159 Genetic Variants Now Known to Be Associated With MS
- MS Research Roundup: October 16, 2014
- New Myelin Required to Learn a New Task
- Deep Brain Stimulation Helpful in Some Patients With MS Tremor
- Immune Attack: Primary or Secondary?
- Benign MS Expresses Itself
- Beyond Reasonable Doubt: The vitamin D piece of the MS puzzle
- Partnership and Consent in MS Decision-Making
- Low Testosterone Linked to Disability in Men With MS
- MS Family Planning 201: Breastfeeding, DMTs, and the Risk of Postpartum Relapse
- The Immunopathogenesis of MS
- Annual Relapse Rates in Placebo Groups Decreasing Over Time
- The MS Galaxy: Authors of Phase 3 Clinical Trials
- MRI Detects Early MS-Like Changes in Rare Eye Disease
- New iPad App Tracks MS Patient Course
- Unusual association of Arnold-Chiari malformation and vitamin B12 deficiency.
- Pregnancy’s Secret Weapon?
- Exploiting the EBV-MS Link to Quell Secondary Progressive Disease
- Eight cases of insular sclerosis of the brain and spinal cord.
- First-in-class thyrotropin-releasing hormone (TRH)-based compound binds to a pharmacologically distinct TRH receptor subtype in human brain and is effective in neurodegenerative models.
- Clinical Trials in Multiple Sclerosis
- Salt Sampler
- Papers: 3 Oct 2014 - 10 Oct 2014
- Is Normal Pressure Hydrocephalus A Component of Multiple Sclerosis Pathology?